Rare highly malignant adenocarcinoma producing mucin. Most commonly found in stomach (56% of cases). Less frequently occurs in breast, gallbladder, urinary bladder, and pancreas. Less than 1% prevalence in colorectal cancers
Protocol applies to all stomach carcinomas, including EGJ involvement >2 cm. Excludes EGJ tumors, neuroendocrine tumors, lymphomas, and sarcomas. Protocol requires synoptic reporting format for accreditation purposes
Gastric adenocarcinoma is an epithelial-derived malignant tumor arising from stomach. Lymphoepitheliomalike carcinoma was first described by Watanabe et al in 1976. Mucinous adenocarcinoma develops from stomach mucosa, maintaining glandular differentiation. Gastric adenocarcinoma with chief cell differentiation is a rare variant
CDH1 gene produces E-cadherin protein for epithelial cell membrane. E-cadherin helps cells stick together and form organized tissues. Protein acts as tumor suppressor, preventing uncontrolled cell growth. E-cadherin and p120-catenin interactions crucial for craniofacial development
Sixth edition published in July 2021 incorporating new evidence. Guidelines consist of Treatments and Clinical Questions sections. Committee followed MINDS methodology for guideline compilation. Number of Clinical Questions increased to 32 items
Stomach cancer can occur anywhere in stomach, most common at gastroesophageal junction. Average age of diagnosis is 68, with 60% occurring in patients over 65. New cases have decreased by 1.5% yearly for last 10 years